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[SPECIAL REPORT: DEPRESSION] 
Multimodal Markers and Biomarkers of Treatment 
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The emergence of precision approaches to treating depression could hardly be more essential: 
depression is now deemed to have the highest disability burden worldwide of all illnesses, and 
inadequate response to treatment compounds the issue.1 A substantial minority of patients 
experience multiple treatment resistant depression (TRD) and consequential chronic and/or 
recurrent illness. The burden of TRD is challenging to quantify but extensive, partly due to the 
associations with increased physical as well as psychiatric morbidity and mortality that in turn 
present excessive costs to health care and economic sectors, in addition to being detrimental to 
individual and caregiver wellbeing. Despite this, TRD has received little attention; as a result, 
treatment guidelines have struggled to provide evidence-based recommendations for TRD, and 
we are unable to proactively prevent treatment-resistance.2 
 The field of precision medicine has initiated significant advancements in the treatment of 
various physical illnesses in recent years.3 Psychiatric research is currently looking at ways to 
predict response to treatment for a range of disorders including major depressive disorder 
(MDD) because of the multitude of treatment options and relatively poor response rates to 
commonly prescribed interventions. 
 
Types of therapeutic markers 
The use of biomarkers to assist with optimizing treatment decisions for depression has been 
receiving increasing attention. Streams of biomarker “omics” may be representative of one or 
more biological systems and may be measured directly or indirectly in humans. “Omics” 
describes biomarkers that can be measured across the whole of each level (see Figure): Findings 
of abnormal genomic, epigenomic, transcriptomic, proteomic, and metabolomic and 
microbiomic profiles in individuals with psychiatric diagnoses—particularly MDD—have been 
widespread.4 Although the findings represent potential diagnostic biomarkers, inconsistencies 
between studies render single biomarkers ineffectual as replacements for current diagnostic tools. 
Indeed, the potential for a diagnostic biomarker (or biomarkers) for depression are viewed with 
much skepticism, not least because it is difficult to see how they could ever outperform current 
diagnostic criteria. For example, neither diagnosis nor antidepressant treatment would be 
recommended for a patient who biologically scored positive for depression but manifested no 
discernible psychological or functional symptoms. 
 “Prognostic” biomarkers might be useful for detecting patient vulnerabilities for TRD or 
chronic depression regardless of which treatment is selected, while “predictive” biomarkers 
assess the likelihood of success with a specific intervention.5 Both prognostic and predictive 
therapeutic markers for depression have been explored for a wide variety of biological and non-
biological factors. 
 It is outside the scope of this article to detail which markers in particular can be used as 
aids for finding optimum treatment strategies for number of reasons: there are too many potential 
markers; we have not nearly enough evidence or knowledge to make useful prediction estimates; 
and, it is likely that the most accurate prediction models will be of such considerable complexity 
that they cannot be practically applied with current approaches. Instead, I first look at a few 
recent findings that indicate promise for this field and follow with an overview of the challenges 
and barriers that must be overcome before therapeutic markers can effectively be utilized in 
practice. 
 
The inflammation revolution 
The most widespread biological research in the last decade has focused on inflammation. One of 
the most striking findings has been regarding macrophage migration inhibitory factor and 
interleukin-1β (IL-1β) mRNA. Cattaneo and colleagues6 specified cut-off values for biomarker 
levels; the highest levels were categorized as non-responders. Data showed a positive predictive 
value and specificity of 100% (as well as negative predictive values of ~85% and sensitivity of 
~55%). Following the article release, news reports suggested that a blood test could be used to 
predict response to antidepressants in this way. This inference was premature inference for a 
number of reasons: limitations in sensitivity, sample size, and lack of replication. 
 The findings might be explained by the existence of a modifying factor such as 
chronicity: elevated IL-1β has been indicated in patients with chronic depressive episodes and 
high risk for treatment resistant symptoms.7 If these two gene expression markers are established 
as predictors of escitalopram or nortriptyline response (as Cattaneo et al. found) in future studies, 
many questions remain; for instance, do these biomarkers represent prescriptive predictors of 
specific antidepressants or prognostic markers of response regardless of treatment? 
 Another unanswered question is how gene expression relates to other streams of 
biomarker (see Figure). Increasing attention is being paid to the microbiome. In support of the 
findings of Cattaneo and colleagues, elevations in circulating inflammatory proteins have been 
widely linked to poorer treatment response to various antidepressant treatments but a better 
response to anti-inflammatory treatments than those with normal inflammatory activity.8,9 
 
It’s not all about inflammation 
Promising biomarkers have been posited across a range of biological systems, including 
neurotransmitter, cell proliferation, and metabolic and endocrine systems (which in themselves 
operate across omics levels). Cortisol levels could be a prognostic or prescriptive therapeutic 
marker. Depressed patients with higher levels of cortisol respond less well to psychological (and 
to serotonergic) therapies than those with lower levels.10 This relationship has not been 
consistently found in all studies and many other biological markers have predicted response to 
various treatments for depression (i.e., inflammatory cytokines, c-reactive protein, brain-derived 
neurotropic factor, genetic and other biological markers). 
 Moreover, numerous non-biological constructs have preceded poor antidepressant 
response and have been associated with many biomarkers, such as childhood trauma, personality 
disorder, psychosocial stress, chronicity and treatment-resistance of depressive illness. Taken 
together, it appears improbable that a single marker of response to any treatment for depression 
can be identified without accounting for multiple factors. And modelling these variables together 
to understand the interactions between treatment mechanisms and outcome is a huge challenge 
that requires large patient samples and advanced computational models. 
 
The search for homogeneous subtypes 
Across biological and non-biological research one factor that is discussed again and again, but 
has not been fully addressed, is the heterogeneity of depression. One patient can present 
strikingly differently from another, but on the whole depression is viewed as a single disorder. 
Despite attempts, clinically homogenous subgroups have not been identified that map onto which 
treatments people respond to, or even that consistently associate with specific biomarkers, which 
need to be delineated before therapeutic markers can be established. 
 Some subtypes have been commonly used, such as atypical or melancholic features and 
these have to some extent, been linked with biological features: patients with atypical depression 
may present with attenuated baseline cortisol levels but higher inflammatory activity.11 A 
somatic subtype may comprise patients with more prominent biological abnormalities, 
particularly related to inflammation (with prominent symptoms associated with sickness 
behavior), and this subpopulation might be at increased risk for non-response to monotherapy or 
low-intensity treatments for depression.9 This may exemplify the need for multimodal modelling 
of therapeutic markers in depression, specifically through combining clinical and biological 
factors. As well as proving useful for guiding a precision medicine “what works for whom” 
agenda, multimodal examination might also help to solve some of the other problems discussed 
above. 
 
Clinician versus computer: clinical implications 
In the absence of precision markers for treating depression, in contrast with a wide array of 
potential interventions to select from, clinicians are left to use their own clinical insight and 
intellect (in addition to communication with patients) to select the treatment most likely to 
achieve remission. This can work well; for example, a specialist national inpatient service in the 
UK for patients with severe TRD has utilized clinical expertise alongside multidisciplinary 
treatments to achieve very high rates of treatment response that have been sustained one year 
after discharge.12 While this indicates that even for complex affective disorders, considering a 
patient’s illness holistically and insightfully can reach a successful outcome for many 
individuals, this does not come without significant time investment and domain-specific 
expertise. Furthermore, findings suggest that statistical models consistently outperform clinical 
decision making in predicting response.13 
 Predictive models are not yet sophisticated enough to be clinically useful and statistical 
modelling has its own challenges, including but not limited to overfitting of data, underpowered 
sample size, or poor quality data from large studies. Many researchers and clinicians believe that 
“big data” will catalyze basic science into translational use through mining datasets with large 
numbers of patients and variables (both biological and non-biological) and employing machine 
learning strategies to determine clinically useful algorithms. 
 
What works for whom: a conclusion? 
Especially now that exciting undercurrents are beginning to surface, caution is urged. Not only 
are there thousands of potential therapeutic markers for depression (and more being proposed all 
the time), these often do not consider clinical heterogeneous presentations. Additionally, there 
are many putative reasons for non-response to treatments, including inaccurate diagnosis, life 
events, comorbidities, concurrent treatments, adherence or tolerability issues, duration and dose-
related factors, thousands of permutations of depressive symptom combinations (and treatment 
combinations). 
 Research on therapeutic markers aspires to facilitate a means of maximizing treatment 
response early in the course of illness and bring enhanced care to patients more widely, quickly 
and cheaply. Although this is a noble goal that has the potential to enhance treatment and lessen 
the burden of this complex illness for many individuals, it is not straightforward: Depression is a 
complex phenomenon that co-occurs frequently with many diagnoses and for every triumphant 
anecdote there are a legion of other less-resolved cases. 
 In order to identify prognostic markers of response to treatment for depression, a 
multimodal model will almost certainly be required, with its components not yet ascertained. 
Models of prescriptive markers of response—predicting who will respond well to specific 
individual treatments—are likely farther away. Extensive work is ongoing in this area, and 
advancements in prediction modelling will accelerate progress. To accurately answer the 
question “what works for whom,” we need to maintain hope, patience and determination. 
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Figure 
Biomarker “omics” that can be measured across the whole of each biological ‘level’ (i.e. 
genome, epigenome, transcriptome, proteome, metabolome, microbiome).  
Genomics→all genetic material 
Epigenomics→all molecules that modify gene activity 
Transcriptomics→all messenger RNS expressed from genes 
Proteomics→all proteins expressed 
Metabolomics→all small-molecule metabolites 
Microbiomics→the total genomes of all microorganism in the body 
 
 
